Navigation Links
Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
Date:4/14/2008

SAN FRANCISCO, April 14 /PRNewswire-FirstCall/ -- Positive preclinical data was presented by Nektar Therapeutics (Nasdaq: NKTR) this week for its lead oncolytic candidate, NKTR-102 (PEG-irinotecan), which demonstrated enhanced anti-tumor activity in a mouse xenograft model of colorectal cancer when co-administered with bevacizumab. Presented at the American Association for Cancer Research (AACR) Annual Meeting 2008 in San Diego, California, the data also featured the enhanced pharmacokinetic profile and tolerability of NKTR-102, as compared to irinotecan in animal models.

NKTR-102 is a PEGylated form of irinotecan developed using Nektar's innovative small molecule PEGylation technology platform. NKTR-102 is currently in a Phase 2 development program to evaluate its safety and efficacy as a second-line colorectal cancer therapy in combination with cetuximab. Nektar had previously announced its intention to expand the NKTR-102 Phase 2 clinical development program later this year with additional indications.

"NKTR-102 is demonstrating important promise as a solid tumor treatment that could be used in a number of critical cancer care regimens," said Tim Riley, Ph.D., Vice President of PEGylation Research at Nektar. "These data reinforce our confidence in the potential of our small molecule PEGylation technology platform to improve the therapeutic potential of oncolytics that are widely used to treat cancer. We look forward to presenting new data from our clinical trials at additional major oncology conferences this year."

In the preclinical studies presented at AACR, NKTR-102 was co-administered with bevacizumab to evaluate the effects of combination therapy. The combination therapy had an additive effect, inhibiting tumo
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
2. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
3. Human Genome Sciences Presents New Data Showing Anti-Tumor Activity And Safety Of Trail Receptor Antibodies In Combination With Chemotherapy
4. Updated Phase 1 Data for Exelixis XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
5. Nuvelo Announces Preclinical Data for NU206 Demonstrating Potent Therapeutic Activity in Oral Mucositis Models
6. Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months
7. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007
8. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722
9. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
10. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
11. Evotecs EVT 101 Shown to Penetrate the Brain in Man and to Modulate Brain Activity During the Performance of Cognitive Tasks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)...   Royal Philips (NYSE: ... and eCareCompanion telehealth applications have received 510(k) clearance ... A part of Philips Hospital to Home,s ... are focused on patient care within the home ... available through the cloud-based digital health platform, which ...
(Date:10/1/2014)... LAUSANNE , Suisse, October 1, 2014 /PRNewswire/ ... génomique clinique et dans le domaine de l,analyse ... a lancé aujourd,hui une solution de diagnostic in ... d,exécuter une analyse complète de la mucoviscidose dans ... d,identifier et de caractériser tous les types de ...
(Date:9/30/2014)... 30, 2014  Wrightington, Wigan ... MDRX ) are delighted to announce WWL,s ... new health information system. The system will be implemented ... the way WWL delivers healthcare in the future. ... record of on-time and on-budget system implementations as well ...
Breaking Medicine Technology:Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 2Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 3Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 4Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 2Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 3Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 2Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 3Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 4
... , July 28 HemaQuest Pharmaceuticals, a ... sickle cell disease, beta thalassemia and EBV-related cancers, announced ... to its Series B financing by new investor, Latterell ... financing to $16M . The financing is intended ...
... July 27 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. ... Proxy Advisory Services,("ISS"), a leading independent proxy voting and corporate ... River,s proposed,acquisition of WuXi. Two other proxy advisory services, Glass ... the,transaction. , , ...
Cached Medicine Technology:HemaQuest Pharmaceuticals Raises Additional $4M to Bring Total to $16M in Series B Financing 2ISS Recommends That WuXi Shareholders Vote for Proposed Combination With Charles River 2ISS Recommends That WuXi Shareholders Vote for Proposed Combination With Charles River 3ISS Recommends That WuXi Shareholders Vote for Proposed Combination With Charles River 4ISS Recommends That WuXi Shareholders Vote for Proposed Combination With Charles River 5
(Date:10/1/2014)... October 01, 2014 Lifeinsurance-policy.com has ... the best life insurance prices for smokers. , Smoking ... insurance premiums. Comparing quotes is the best method to ... quotes for customers who need coverage. , Whole ... duration of the policy. Since the coverage is permanent, ...
(Date:10/1/2014)... 2014 Phoseon Technology, the pioneer in ... expand the business worldwide. This rapid growth includes increased ... for manufacturing efforts. The company has experienced average annual ... and expects this growth to continue in the future ... worldwide adoption. , “We are very pleased that ...
(Date:10/1/2014)... Farmington Company today announced it ... and visual identity helping brokers, consultants and companies ... to create greater benefit communication synergies. They unveiled ... empowering customers to better leverage Farmington Company’s industry-tested ... of the rebrand is the refreshed tagline: For ...
(Date:10/1/2014)... A new genetic finding from Duke Medicine suggests that ... depression might also be hard-wired to gain weight when ... disease. , An estimated 13 percent of people, all ... and knowing this could help them reduce heart disease ... and stress management. , "Genetic susceptibility, psychosocial stress and ...
(Date:10/1/2014)... 2014 Between 23 million and 50 ... according to figures from the National Institutes of Health ... and many of them have something else in common: ... celiac disease. Gluten Free Therapeutics, makers of CeliVites ... celiac disease by publishing a series of blog posts ...
Breaking Medicine News(10 mins):Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3
... COVER: "Splitsville" (p. 46). Senior Editor David J. Jefferson ... classmates from Ulysses S.,Grant High School, class of ,82 ... interviews with former classmates, Jefferson tells the,stories of those ... the nuclear,family, the first for which divorce was just ...
... The Barbara Ann Karmanos,Cancer Institute researchers today presented, ... in San Diego, CA, the potential benefits,of Thymoquinone ... black seeds (Nigella,sativa), in treating pancreatic cancer., ... black seeds have been consumed in Asia, Africa ...
... April 12 Hundreds of,Service Employees International Union ... tonight, renouncing recent actions by the,California Nurses Association ... members made their voices heard during the Labor,Notes ... Rose,Ann DeMoro was scheduled to speak but cancelled ...
... condoms, vasectomy , , SATURDAY, April 12 (HealthDay News) -- For now, ... meager choices: A vasectomy -- meant to be permanent -- and ... is under development and that more choices will be here soon. ... off, but it,s getting closer. , "It has been ...
... with older, poorer, less educated populations likely due to ... , ANN ARBOR, Mich. More than a third of ... a huge increase from just a decade ago and a ... of Michigan study reveals major gaps in the availability of ...
... Home Operator Continuing to Jeopardize Residents, Care, ... Millbrae Convalescent Hospital will launch their second strike ... management,s unwillingness to,bargain fairly over the workers, proposals ... set to begin at 6 a.m. on Tuesday, ...
Cached Medicine News:Health News:NEWSWEEK: Media Lead Sheet/April 21, 2008 Issue (on newsstands Monday, April 14). 2Health News:NEWSWEEK: Media Lead Sheet/April 21, 2008 Issue (on newsstands Monday, April 14). 3Health News:NEWSWEEK: Media Lead Sheet/April 21, 2008 Issue (on newsstands Monday, April 14). 4Health News:NEWSWEEK: Media Lead Sheet/April 21, 2008 Issue (on newsstands Monday, April 14). 5Health News:Karmanos Researchers Report Enhanced Chemosensitivity of Pancreatic Cancer Cells by Black Seed Component 2Health News:Karmanos Researchers Report Enhanced Chemosensitivity of Pancreatic Cancer Cells by Black Seed Component 3Health News:SEIU Members Stand Up for the Future of the Labor Movement and the Interests of All Workers 2Health News:Male Contraception: Progress Slow but Steady 2Health News:Male Contraception: Progress Slow but Steady 3Health News:National hospice study reveals gaps in service 2Health News:National hospice study reveals gaps in service 3Health News:National hospice study reveals gaps in service 4
Batch Detection of Soluble Fibrin Monomer Complexes by the Hemagglutination Technique, 40 tests....
For use with catalog #0540....
Enzyme Immunoassay of D-Dimer by ELISA Method, 96 tests....
Lupus Anticoagulant-Sensitive APTT Reagent.Cephalin with particulate activator (silica), freeze-dried....
Medicine Products: